Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar;16(3):182-241.
doi: 10.11909/j.issn.1671-5411.2019.03.014.

2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension

Joint Committee for Guideline Revision

2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension

Joint Committee for Guideline Revision. J Geriatr Cardiol. 2019 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Announcement of conflict of interest (This list is in no particular order.): During the revision of this guideline, AstraZeneca Investment (China) Co., Ltd., Bayer Health Care Co., Ltd., Beijing Double-Crane Pharmaceutical Co., Ltd., Sinopharm Holding Distribution Co., Ltd., Hanhui Pharmaceutical Co., Ltd., Hangzhou MSD Pharmaceutical Co., Ltd., Lepu Pharmaceutical Technology Co., Ltd., Merck Serono Co., Ltd., Sanofi (Hangzhou) Pharmaceutical Co., Ltd., Shenzhen Salubris Pharmaceutical Co., Ltd., Servier (Tianjin) Pharmaceutical Co., Ltd., Tianjin Tanabe Pharmaceutical Co., Ltd., Tibet Kangzhe Pharmaceutical Development Co., Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Ltd., Beijing Nuohe Xinkang Gene Technology Co., Ltd., and Beijing Precision Health Management of Hypertension & Angiocardiopathy Co., Ltd. supported the conferences of revision, but did not participate in or influence the guideline's academic content and evidence review. The guideline remains independent.

Figures

Figure 1.
Figure 1.. Cumulative incidence of hypertension in different genders and baseline age groups from 1991 to 2000
Figure 2.
Figure 2.. Evaluation and monitoring procedures for newly diagnosed hypertension.
Diagnostic criteria of hypertension for ABP is daytime mean SBP ≥ 135 mmHg or DBP ≥ 85 mmHg, nighttime mean SBP ≥ 120 mmHg or DBP ≥ 70 mmHg, or 24-h mean SBP ≥ 130 mmHg or DBP ≥ 80 mmHg; that criteria for home blood pressure is mean SBP ≥ 135 mmHg or DBP ≥ 85 mmHg. Moderate risk patients with BP ≥ 160/100 mmHg should start drug therapy immediately. ABPM: ambulatory blood pressure monitoring; BP: blood pressure; CBPM: clinic blood pressure monitoring; DBP: diastolic blood pressure; HBPM: home blood pressure monitoring; SBP: systolic blood pressure.
Figure 3.
Figure 3.. Flowchart for the choice of initial single versus combination antihypertensive therapy.
A: ACEI or ARB; B: β-blockers; C: dihydropyridines CCB; D: thiazide-type diuretics; F: fixed-dose combination drugs. *For those with BP ≥ 140/90 mmHg and at high risk, initial low-dose combination therapy can also be recommended; **Including dosage titration and sequential addition of other agents to achieve BP target. ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blockers; BP: blood pressure; CCB: calcium channel blockers.
Figure 4.
Figure 4.. Flow chart for diagnostic evaluation of hypertension in children.
DBP: diastolic blood pressure; SBP: systolic blood pressure.
See this image and copyright information in PMC

References

    1. Wang Z, Chen Z, Zhang L, et al. Status of Hypertension in China: results from the China hypertension survey, 2012–2015. Circulation. 2018;137:2344–2356. - PubMed
    1. Li LM, Rao KQ, Kong LZ, et al. [Survey on Nutrition and Health Status of Chinese Residents in 2002] Chin J Epidemiol. 2005;26:478–484. [In Chinese] - PubMed
    1. Hu YS, Yao CH, Wang WZ, et al. [Prevalence of hypertension in some ethnic groups in China in 2002] Wei Sheng Yan Jiu. 2006;35:573–575. [In Chinese] - PubMed
    1. Gu D, Wildman RP, Wu X, et al. Incidence and predictors of hypertension over 8 years among Chinese men and women. J Hypertens. 2007;25:517–523. - PubMed
    1. Lewington S, Lacey B, Clarke R, et al. The burden of hypertension and associated risk for cardiovascular mortality in China. JAMA Intern Med. 2016;176:524–532. - PubMed

LinkOut - more resources